Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Early Parkinson Disease (Early PD) Clear all
Completed Phase 2 Interventional

Investigation of Cogane (PYM50028) in Early-stage Parkinson's Disease (CONFIDENT-PD)

NCT01060878
View directory record Official record
Conditions
Parkinson's Disease
Interventions
PYM50028, Placebo
Drug
Lead sponsor
Phytopharm
Industry
Eligibility
35 Years to 75 Years
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
41
States / cities
Scottsdale, Arizona • Irvine, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2013 · Synced Jun 10, 2026, 2:21 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).

NCT00601523
View directory record Official record
Conditions
Parkinson Disease
Interventions
Placebo, Pramipexole
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
30 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
10
States / cities
Sun City, Arizona • Tempe, Arizona • La Jolla, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2014 · Synced Jun 10, 2026, 2:21 AM EDT
Completed Phase 2 Interventional Results available

A 18-month Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants With Early-stage Parkinson's Disease

NCT04658186
View directory record Official record
Conditions
Early-stage Parkinson's Disease
Interventions
UCB0599, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
40 Years to 75 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
57
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2025 · Synced Jun 10, 2026, 2:21 AM EDT
Completed Phase 4 Interventional Results available

A Randomized, Double-blind, Active (Pramipexole 0.5 mg Tid) and Placebo Controlled, Study of Pramipexole Given 0.5 mg and 0.75 mg Bid Over 12-week Treatment in Early Parkinson's Disease (PD) Patients

NCT00402233
View directory record Official record
Conditions
Parkinson Disease
Interventions
Pramipexole, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
31 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
39
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Fountain Valley, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 15, 2014 · Synced Jun 10, 2026, 2:21 AM EDT
Completed Phase 3 Interventional Results available

Study of Urate Elevation in Parkinson's Disease, Phase 3

NCT02642393
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Inosine, Placebo
Drug
Lead sponsor
Michael Alan Schwarzschild
Other
Eligibility
30 Years and older
Enrollment
298 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
61
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Jun 10, 2026, 2:21 AM EDT
Completed Phase 3 Interventional Results available

Fixed-Dose Trial in Early Parkinson's Disease (PD)

NCT04201093
View directory record Official record
Conditions
Parkinson Disease
Interventions
Tavapadon, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years to 80 Years
Enrollment
529 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Fountain Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2025 · Synced Jun 10, 2026, 2:21 AM EDT
Completed Not applicable Interventional

Pre-Active PD: Looking At Physical Activity Behavior Change in Parkinson's Disease

NCT05308238
View directory record Official record
Conditions
Parkinson Disease
Interventions
Occupational therapy intervention group, Disease management education group
Behavioral
Lead sponsor
San Jose State University
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
2
States / cities
San Jose, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Jun 10, 2026, 2:21 AM EDT
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.

NCT07214974
View directory record Official record
Conditions
Mild Cognitive Impairment (MCI), Early Stages of Cognitive Decline, Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis, Alzheimer's Disease and Related Dementias, Parkinson's Disease, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations, Dementia (Diagnosis), Dementia MCI (Mild Cognitive Impairment)
Interventions
Structured wellness care, Wearable brain-computer interface devices, Stem Cell Therapy - Experimental, Control - Placebo Comparator
Behavioral · Device · Biological + 1 more
Lead sponsor
Noah Tech, Corp.
Industry
Eligibility
55 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Palisades Park, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jun 10, 2026, 2:21 AM EDT
Completed No phase listed Observational

Measures of Motor Impairment in Early Parkinson's Disease

NCT00291265
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
30 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jun 10, 2026, 2:21 AM EDT
Not listed Phase 1 Interventional

A Study of Weekly Subcutaneous Injections of SER-214 in Subjects With Parkinson's Disease (PD), to Determine the Safety, Tolerability and Pharmacokinetic (PK) Profile of SER-214

NCT02579473
View directory record Official record
Conditions
Parkinson's Disease
Interventions
SER-214
Drug
Lead sponsor
Serina Therapeutics
Industry
Eligibility
40 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
4
States / cities
Birmingham, Alabama • Hallandale, Florida • Augusta, Georgia + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2023 · Synced Jun 10, 2026, 2:21 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

NCT06966700
View directory record Official record
Conditions
Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
Interventions
Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
53
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 10, 2026, 2:21 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Novel Shoe Device NUSHU to Measure Gait Analysis in Parkinson's Patients

NCT06975059
View directory record Official record
Conditions
Parkinson's Disease (PD)
Interventions
NUSHU shoe
Device
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2030
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jun 10, 2026, 2:21 AM EDT
Completed Phase 3 Interventional

An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients

NCT00335374
View directory record Official record
Conditions
Early Stage Parkinson's Disease
Interventions
Pardoprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
14
States / cities
Birmingham, Alabama • Oceanside, California • Oxnard, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2009 · Synced Jun 10, 2026, 2:21 AM EDT
Completed Phase 2 Interventional

Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)

NCT04995081
View directory record Official record
Conditions
Parkinson Disease
Interventions
Biological/Vaccine: Allogeneic HB-adMSCs, Placebo
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
45 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Dec 23, 2025 · Synced Jun 10, 2026, 2:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wearable Assessments in the Clinic and Home in PD

NCT03681015
View directory record Official record
Conditions
Parkinson Disease
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
30 Years and older
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
17
States / cities
Sun City, Arizona • San Francisco, California • Aurora, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 10, 2026, 2:21 AM EDT
Completed Phase 3 Interventional Results available

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

NCT05357989
View directory record Official record
Conditions
Parkinson's Disease, Idiopathic
Interventions
buntanetap/posiphen, Placebo
Drug
Lead sponsor
Annovis Bio Inc.
Industry
Eligibility
40 Years to 85 Years
Enrollment
523 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
43
States / cities
Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2025 · Synced Jun 10, 2026, 2:21 AM EDT
Not yet recruiting Phase 1 Interventional

AAV2-hAADC for Parkinson's Disease (PDCS-01)

NCT07267065
View directory record Official record
Conditions
Parkinson's Disease (PD), Early Onset Parkinson Disease
Interventions
AAV2-hAADC
Drug
Lead sponsor
Krzysztof Bankiewicz
Other
Eligibility
18 Years to 75 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Jun 10, 2026, 2:21 AM EDT
Completed Phase 3 Interventional

An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients

NCT00332917
View directory record Official record
Conditions
Early Stage Parkinson's Disease
Interventions
Pardoprunox
Drug
Lead sponsor
Solvay Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
25
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Fountain Valley, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2009 · Synced Jun 10, 2026, 2:21 AM EDT
Completed Phase 3 Interventional Results available

Flexible-Dose Trial in Early Parkinson's Disease (PD)

NCT04223193
View directory record Official record
Conditions
Parkinson Disease
Interventions
Tavapadon, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years to 80 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
18
States / cities
Fresno, California • Boca Raton, Florida • Maitland, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jun 10, 2026, 2:21 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Early Parkinson's Disease (PD) Cross-Sectional

NCT00817453
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
35 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2011 · Synced Jun 10, 2026, 2:21 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of NE3107 in Early Parkinson's

NCT06757010
View directory record Official record
Conditions
Parkinsons Disease (PD)
Interventions
NE3107, Placebo
Drug
Lead sponsor
BioVie Inc.
Industry
Eligibility
45 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
4
States / cities
Farmington Hills, Michigan • Amherst, New York • Morrisville, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Jun 10, 2026, 2:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Cutaneous Autonomic Pilomotor Testing to Unveil the Role of Neuropathy Progression in Early Parkinson's Disease

NCT03043768
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Not listed
Lead sponsor
GWT-TUD GmbH
Other
Eligibility
35 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Jun 10, 2026, 2:21 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

A Study to Analyze Symptoms Prevalent in Early PD (Dysphonia, Tremor)

NCT04288804
View directory record Official record
Conditions
Parkinson Disease
Interventions
Smartphone microphone sensor, Smartphone accelerometer sensor
Device
Lead sponsor
Goalspal LLC
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Pleasanton, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced Jun 10, 2026, 2:21 AM EDT
Active, not recruiting No phase listed Observational

Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

NCT05699460
View directory record Official record
Conditions
Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy
Interventions
This is an observational study.
Other
Lead sponsor
AskBio Inc
Industry
Eligibility
35 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
7
States / cities
Irvine, California • Boca Raton, Florida • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Jun 10, 2026, 2:21 AM EDT